Dry Eye Syndrome Clinical Trial
Official title:
A Randomized, Double-masked, Controlled, Non-inferiority Study to Evaluate Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops Given 4 Times a Day for 4 Weeks & 1 Week Follow-up in Subjects With Dry Eye
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms
of discomfort, visual disturbance, and tear film instability with potential damage to the
ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation
of the ocular surface.
Lubricin is a mucin-like glycoprotein originally discovered in synovial fluid, as a secreted
product of cells that line the joint tissues, which is present at the surface of articular
cartilage and it has been investigated on its roles at the ocular surface, in normal and
pathologic conditions such as dry eye.
The objective of the study is to assess the tolerability, safety and efficacy of Lubricin eye
drops solution administered over 4 weeks versus sodium hyaluronate (Na-HY) eye drops solution
in subjects with moderate dry eye.
Dry eye, or keratoconjunctivitis sicca, is a chronic inflammatory condition of the ocular
surface that may cause severe symptoms and visual impairment. The 2007 international dry eye
workshop (DEWS) defined the disease as follows: "Dry eye is a multifactorial disease of the
tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear
film instability with potential damage to the ocular surface. It is accompanied by increased
osmolarity of the tear film and inflammation of the ocular surface".
Lubricin is a mucin-like glycoprotein originally discovered in synovial fluid, as a secreted
product of cells that line the joint tissues, which is present at the surface of articular
cartilage.
In vitro studies have shown that lubricin in saline buffer acts as a lubricant between
various surfaces, as well as in synovial fluid, providing evidence that lubricin is a
principal lubricating protein in joints. Besides the lubricating property, lubricin has been
shown to exert anti-adhesive action, strain energy dissipation, and a protective effect on
underlying cells.
Lubricin has been investigated on its roles at the ocular surface, in normal and pathologic
conditions such as dry eye. In fact, Lubricin is a natural human protein with most potent
lubricant and anti-adhesive properties present on the ocular surface and on meibonian gland.
The presence of this protein at the ocular surface was first described by the team of
Sullivan D.
Based on the available preclinical lubricin studies may be an important barrier to the
development of corneal and conjunctival epitheliopathies in dry eyes and its use as a novel
lubricating and anti-adhesive eye drop is under investigation in this clinical investigation.
This clinical investigation has been designed to demonstrate that a Lubricin 150 µg/ml eye
drop formulation is non-inferior to the currently most-widely used ocular surface lubricant
sodium hyaluronate 0.13% in improving signs and symptoms in patients with moderate dry eye.
Up to now, there are no known anticipated adverse events associated with the use of lubricin,
anyway the occurrence of side effects cannot be excluded.
It must be considered that topical treatment with lubricin or hyaluronic acid could cause
local irritation or allergic reactions. There are no known contraindications to the use of
lubricin or hyaluronic acid eye drops. All examinations and assessments that will be carried
out during this study are non-invasive, are commonly used in the management of subjects with
dry eye and pose no risk to the subjects. There are no known contraindications to the use of
lubricin or hyaluronic acid eye drops. No data are available about the embryo and fetal
toxicity, therefore the experimental treatment will not be allowed to pregnant women or
nursing mothers and women of childbearing potential not using appropriate birth control
methods.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02597803 -
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
|
Phase 2/Phase 3 | |
Completed |
NCT02522312 -
A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
|
N/A | |
Completed |
NCT01863368 -
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
|
N/A | |
Completed |
NCT01753752 -
Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation
|
Phase 2 | |
Completed |
NCT01753687 -
Correlation of Different Signs for Assessment of Dry Eye Syndrome
|
N/A | |
Completed |
NCT01198782 -
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
|
Phase 4 | |
Completed |
NCT01212471 -
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
|
Phase 3 | |
Completed |
NCT01162954 -
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00544713 -
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery
|
N/A | |
Completed |
NCT00535054 -
Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms
|
N/A | |
Completed |
NCT00344721 -
A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
|
N/A | |
Completed |
NCT03830359 -
Efficacy, Safety of T2769 in Dry Eye Disease
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02758327 -
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
|
Phase 4 | |
Completed |
NCT01970917 -
Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects
|
Phase 4 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Completed |
NCT02092207 -
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01541891 -
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT01252121 -
Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline
|
N/A | |
Completed |
NCT00765804 -
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
|
Phase 2 |